BMEA
Biomea Fusion Inc

2,274
Mkt Cap
$96.16M
Volume
1.68M
52W High
$3.08
52W Low
$0.8719
PE Ratio
-0.57
BMEA Fundamentals
Price
$1.25
Prev Close
$1.36
Open
$1.40
50D MA
$1.33
Beta
1.56
Avg. Volume
1M
EPS (Annual)
-$3.83
P/B
5.18
Rev/Employee
$0.00
$90.58
Loading...
Loading...
News
all
press releases
Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib
Biomea Fusion (NASDAQ: BMEA) shares rose Friday after the company reported positive Phase II data for icovamenib in type 2 diabetes, highlighting durable efficacy and a favorable safety profile.read...
Benzinga·3d ago
News Placeholder
More News
News Placeholder
Biomea Fusion Details Diabetes, Obesity Pipeline at Citizens Conference, Sees Cash Runway to Q1 2027
Biomea Fusion (NASDAQ:BMEA) outlined its focus on diabetes and obesity at the Citizens Life Sciences Conference, highlighting two internally developed programs and a series of clinical milestones...
MarketBeat·4d ago
News Placeholder
Biomea Fusion Spotlights Durable Diabetes Data, Oral GLP-1 Weight-Loss Program at Oppenheimer Conf.
Biomea Fusion (NASDAQ:BMEA) outlined progress on its clinical-stage pipeline during an Oppenheimer virtual conference appearance featuring CEO Mick Hitchcock and COO Ramses Erdtmann. The company...
MarketBeat·18d ago
News Placeholder
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of "Moderate Buy" from Analysts
Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten analysts that are presently covering the firm, Marketbeat reports. One...
MarketBeat·30d ago
News Placeholder
Biomea Fusion (NASDAQ:BMEA) Shares Down 3% - What's Next?
Biomea Fusion (NASDAQ:BMEA) Stock Price Down 3% - Should You Sell...
MarketBeat·1mo ago
News Placeholder
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Rating of "Moderate Buy" by Analysts
Shares of Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the ten ratings firms that are presently covering the stock, MarketBeat...
MarketBeat·2mo ago
News Placeholder
Biomea Fusion Spotlights Diabetes, Obesity Pipeline at JPMorgan Conference, Sets 2026 Milestones
Biomea Fusion (NASDAQ:BMEA) highlighted two clinical-stage programs focused on diabetes and obesity during a presentation at the 44th Annual JPMorgan Healthcare Conference, with CEO Mick Hitchcock...
MarketBeat·2mo ago
News Placeholder
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of "Moderate Buy" from Brokerages
Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the firm, MarketBeat Ratings...
MarketBeat·3mo ago
News Placeholder
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine analysts that are presently covering the company, Marketbeat Ratings...
MarketBeat·3mo ago
News Placeholder
Biomea Fusion (NASDAQ:BMEA) Price Target Cut to $6.00 by Analysts at Citigroup
Citigroup reduced their price objective on Biomea Fusion from $7.00 to $6.00 and set a "buy" rating on the stock in a research report on Monday...
MarketBeat·4mo ago
<
1
2
...
>

Latest BMEA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.